Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
View Paradigm4’s catalog of peer-reviewed articles and posters.
Browse the glossary of terms from across the realm of bioinformatics.
Request access to the collection of white papers by Paradigm4.
See how Paradigm4 has transformed the pace of innovation for our clients.
Watch videos from Paradigm4’s library to learn about flexFS, see use cases, and more.
Read interviews, lessons, and insights from academic and industry visionaries.
Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
Zachary Pitluk, Ph.D., Vice President of Life Sciences and Healthcare at Paradigm4, highlights how real insight comes, not from data collection, but from intelligent data curation, computation, and application.
Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. But the value of these systems risks being impaired by bottlenecks in data analysis